KINB2 Antibody

What is CSNK2B and why is it an important target for antibody-based research?

CSNK2B functions as a regulatory subunit of casein kinase II/CK2, where it regulates the basal catalytic activity of the alpha subunit. This constitutively active serine/threonine-protein kinase phosphorylates numerous substrates containing acidic residues C-terminal to the phosphorylated serine or threonine . Recent research has revealed that CSNK2B plays critical roles in antiviral immunity by interacting directly with Interferon Regulatory Factor 1 (IRF1) and modulating its binding to chromatin, thereby promoting expression of key antiviral genes . It also participates in Wnt signaling pathways and mediates various virus-host interactions, making it a valuable target for immunological research .

When designing experiments with CSNK2B antibodies, researchers should consider:

• The specific protein domains they wish to target

• Potential cross-reactivity with other CK2 subunits

• The cellular compartments where CSNK2B is expected to be found (primarily nuclear and cytoplasmic)

• The specific post-translational modifications that might affect antibody recognition

What applications are recommended for commercially available CSNK2B antibodies?

Commercial CSNK2B antibodies, such as the rabbit recombinant monoclonal [EP1995Y], have been validated for multiple applications including:

• Immunohistochemistry on paraffin-embedded tissues (IHC-P)

• Western blotting (WB)

• Immunocytochemistry/Immunofluorescence (ICC/IF)

• Flow cytometry (intracellular staining)

For optimal results in immunoblotting, researchers typically use antibody dilutions between 1:1000-1:5000, depending on the specific antibody and detection system. For immunofluorescence applications, dilutions of 1:100-1:500 are commonly recommended, though optimization for specific experimental conditions is always advised .

For novel applications not previously validated, researchers should conduct preliminary titration experiments and include appropriate positive and negative controls to establish optimal working conditions.

What are the critical considerations for validating CSNK2B antibody specificity?

When validating CSNK2B antibody specificity, researchers should:

• Include genetic controls such as CSNK2B-knockout or knockdown samples to confirm signal specificity

• Test for cross-reactivity with other CK2 subunits (especially CSNK2A1 and CSNK2A2)

• Perform peptide competition assays using the immunizing peptide

• Validate results using multiple antibodies targeting different epitopes of CSNK2B

• Compare results across multiple detection methods (e.g., Western blot and immunofluorescence)

Research has shown that even well-characterized antibodies can produce unexpected results in certain contexts. For example, when studying CSNK2B's role in viral infections, researchers found that antibody detection sensitivity can be affected by virus-induced changes in protein conformation or interactions . Therefore, validation under the specific experimental conditions being studied is essential.

How can researchers optimize immunoprecipitation protocols for studying CSNK2B-protein interactions?

For optimal immunoprecipitation of CSNK2B and its interacting partners:

• Cell lysis conditions:

  • Use mild detergents (0.5-1% NP-40 or Triton X-100) to preserve protein-protein interactions

  • Include phosphatase inhibitors to maintain phosphorylation-dependent interactions

  • Consider crosslinking agents for transient interactions (0.5-2% formaldehyde for 10-15 minutes)

• Antibody selection and binding:

  • Choose antibodies validated for immunoprecipitation applications

  • For studying interactions with IRF1, ensure the antibody epitope doesn't overlap with the IRF1 binding region

  • Pre-clear lysates to reduce non-specific binding

  • Use 2-5 μg antibody per 500 μg of total protein

• Washing conditions:

  • Adjust stringency based on interaction strength (more stringent washes for robust interactions)

  • For phosphorylation-dependent interactions, maintain phosphatase inhibitors in wash buffers

• Controls to include:

  • IgG control matched to the host species of the primary antibody

  • Input sample (5-10% of lysate used for IP)

  • When possible, include a CSNK2B-depleted sample as negative control

When studying CSNK2B-IRF1 interactions specifically, researchers should consider that this complex affects chromatin binding and gene expression, so protocols might need to be adapted to capture these nuclear interactions effectively .

What approaches can be used to study CSNK2B's role in modulating IRF1 binding to chromatin?

To investigate CSNK2B's role in modulating IRF1 chromatin binding:

• Chromatin immunoprecipitation (ChIP) analysis:

  • Use anti-IRF1 antibodies in CSNK2B-depleted versus control cells

  • Focus on known IRF1 target genes like PLAAT4 (RARRES3/RIG1/TIG3)

  • Quantify by qPCR or sequence the immunoprecipitated DNA (ChIP-seq)

• CUT&RUN (Cleavage Under Targets & Release Using Nuclease) profiling:

  • This approach has been successfully used for genome-wide analysis of CSNK2B-dependent IRF1 binding sites

  • It provides higher resolution than traditional ChIP-seq

  • Results have revealed that CSNK2B enhances IRF1 binding to regulatory elements controlling antiviral genes

• Sequential ChIP (Re-ChIP):

  • First immunoprecipitate with anti-IRF1, then with anti-CSNK2B

  • This confirms co-occupancy of both proteins at specific genomic loci

• Functional validation:

  • Correlate binding data with gene expression analysis in CSNK2B-depleted cells

  • Target specific binding sites for mutagenesis to disrupt IRF1 binding

  • Employ reporter assays with wild-type and mutant regulatory elements

Recent studies using these approaches have demonstrated that CSNK2B acts to enhance IRF1 binding to chromatin at most sites, but interestingly causes reduced IRF1 binding at specific loci like AFAP1, revealing context-dependent regulation .

How can CSNK2B antibodies be effectively used in studying antiviral mechanisms?

For studying CSNK2B's role in antiviral immunity:

• Virus infection models:

  • CSNK2B antibodies can be used for immunofluorescence to track protein localization during viral infection

  • Western blotting can monitor CSNK2B levels and post-translational modifications in response to infection

  • Flow cytometry with intracellular staining can quantify CSNK2B in infected versus uninfected cells

• Experimental approach for studying CSNK2B in antiviral responses:

  • Silence CSNK2B expression using siRNA (50% depletion is sufficient to observe effects)

  • Challenge cells with viruses (HAV, DENV, ZIKV have been successfully studied)

  • Measure viral replication via RNA quantification or infectious virus production

  • In parallel, monitor expression of CSNK2B-dependent antiviral genes (e.g., PLAAT4, AFAP1)

• Primary cell models:

  • Primary human hepatocytes (PHHs) have been successfully used with CSNK2B antibodies

  • When working with primary cells, optimize antibody concentrations and detection methods

  • To focus on constitutive antiviral defense, researchers can use JAK inhibitors (e.g., pyridone 6) to suppress induced IFN responses

• Specific considerations:

  • For flavivirus studies (DENV, ZIKV), focus on AFAP1 as a downstream effector

  • For HAV studies, PLAAT4 is a key CSNK2B-IRF1 regulated effector

  • Different viruses may show opposing responses to CSNK2B manipulation due to its dual roles

Research has demonstrated that even modest (50%) CSNK2B depletion in PHHs results in reduced expression of antiviral factors like PLAAT4 and significantly increased viral replication, highlighting the importance of this pathway in constitutive antiviral defense .

How can researchers address specificity issues with CSNK2B antibodies?

When encountering specificity issues with CSNK2B antibodies:

• Background reduction strategies:

  • Increase blocking time and concentration (5% BSA or 5% milk in TBS-T)

  • Optimize antibody dilution through titration experiments

  • Include 0.1-0.3% Triton X-100 in antibody diluent to reduce non-specific binding

  • Use longer but more dilute antibody incubation (overnight at 4°C at 2-3× more dilute)

• Distinguishing between CK2 subunits:

  • Select antibodies targeting unique regions not conserved between subunits

  • Confirm specificity using genetic controls (knockdown/knockout)

  • Consider using antibodies targeting specific post-translational modifications

  • Run appropriate molecular weight controls (CSNK2B: ~25 kDa; CSNK2A: ~45 kDa)

• Confirmation approaches:

  • Use multiple antibodies targeting different epitopes

  • Employ orthogonal detection methods

  • Include peptide competition controls

  • Consider mass spectrometry validation of immunoprecipitated proteins

• Application-specific considerations:

  • For IHC applications, antigen retrieval methods significantly impact specificity

  • For flow cytometry, fixation and permeabilization conditions are critical

  • For IP applications, pre-clearing lysates reduces non-specific binding

What are the key considerations when designing experiments to study CSNK2B-dependent phosphorylation events?

To effectively study CSNK2B-dependent phosphorylation:

• Experimental design:

  • Compare wild-type cells to CSNK2B-depleted cells

  • Include catalytic subunit (CSNK2A1) depletion controls

  • Consider pharmacological inhibitors of CK2 as complementary approaches

  • Be aware that CK2 inhibitors may have cytotoxicity that complicates interpretation

• Detection methods:

  • Phospho-specific antibodies for known CK2 substrates

  • Phospho-proteomics approaches to identify novel targets

  • Phos-tag SDS-PAGE to separate phosphorylated from non-phosphorylated proteins

  • In vitro kinase assays with recombinant proteins

• Focus on known CSNK2B-dependent pathways:

  • AFAP1-Src signaling is phosphorylation-dependent and regulated by CSNK2B

  • Wnt signaling components

  • IRF1-mediated transcriptional regulation

• Controls and validation:

  • Use phosphatase treatment of samples as negative controls

  • Include non-phosphorylatable mutants (S/T to A) of putative targets

  • Validate findings with both genetic (siRNA) and pharmacological approaches

  • Consider the temporal dynamics of phosphorylation events

Research has shown that CSNK2B mediates phosphorylation-dependent activation of AFAP1-Src signaling, which contributes to antiviral effects against flaviviruses. This exemplifies how CSNK2B can regulate protein function through both transcriptional (with IRF1) and post-translational (phosphorylation) mechanisms .

How can CSNK2B antibodies be employed in studying virus-host interactions?

For investigating CSNK2B in virus-host interactions:

• Virus-specific considerations:

  • For Epstein-Barr virus (EBV): CSNK2B interacts with viral EBNA1, increasing association with PML proteins

  • For flaviviruses (DENV, ZIKV): CSNK2B regulates AFAP1 expression and activation

  • For HAV: CSNK2B-IRF1 axis regulates PLAAT4 expression

• Methodological approaches:

  • Co-immunoprecipitation to detect virus-host protein interactions

  • Proximity ligation assay (PLA) to visualize interactions in situ

  • CSNK2B localization changes during infection (immunofluorescence)

  • ChIP analysis to detect altered IRF1 binding during infection

• Experimental design for virus studies:

  • Time-course experiments to capture dynamic changes

  • Compare multiple virus types (CSNK2B has opposing effects on different viruses)

  • Include both genetic (siRNA) and pharmacological (CK2 inhibitors) approaches

  • Consider virus strain differences (e.g., cytopathic vs. noncytopathic HAV)

• Data interpretation challenges:

  • CSNK2B can have seemingly contradictory roles as both antiviral factor and pro-viral cofactor

  • Effects may be virus-specific and cell-type dependent

  • Consider potential effects on both viral and host proteins

  • Be aware of potential compensatory mechanisms

What are the considerations for using antibody-based techniques to study CSNK2B in different cellular compartments?

When investigating CSNK2B in different cellular compartments:

• Subcellular fractionation protocols:

  • Optimize lysis conditions to maintain integrity of compartments

  • Include compartment-specific markers as controls (e.g., GAPDH for cytoplasm, Lamin B1 for nucleus)

  • For membrane-associated CSNK2B, consider detergent solubility profiling

• Immunofluorescence optimization:

  • Fixation methods impact detection (4% PFA for general detection; methanol for certain epitopes)

  • Test different permeabilization methods (0.1-0.5% Triton X-100 vs. 0.1-0.5% saponin)

  • Co-stain with compartment markers (e.g., DAPI for nucleus, phalloidin for actin cytoskeleton)

  • Consider super-resolution microscopy for precise localization

• Context-specific considerations:

  • CSNK2B-IRF1 interactions primarily occur in the nucleus

  • CSNK2B-AFAP1 interactions involve actin cytoskeleton

  • During viral infection, monitor potential translocation between compartments

• Controls and validation:

  • Use multiple antibodies to confirm localization patterns

  • Include CSNK2B-depleted cells as negative controls

  • Consider tagged CSNK2B constructs as complementary approaches

  • Validate key findings with both biochemical and imaging approaches

Research has shown that CSNK2B can function in multiple cellular compartments, regulating transcription in the nucleus through IRF1 interactions while also mediating cytoskeletal regulation through AFAP1-Src signaling pathways .

How can researchers optimize antibody-based detection of CSNK2B in custom binding specificity assays?

For optimizing detection in custom binding assays:

• Phage display considerations:

  • When designing antibody libraries for CSNK2B binding studies, consider multiple binding modes

  • Use computational models to disentangle binding modes associated with different ligands

  • Incorporate biophysics-informed models to predict and generate specific variants

  • Include pre-selection steps to deplete non-specific binders

• Energy function optimization:

  • To obtain cross-specific CSNK2B binding, jointly minimize energy functions associated with desired ligands

  • For specific binding, minimize energy functions for desired targets while maximizing for undesired targets

  • Balance between affinity and specificity in optimization criteria

• Validation approaches:

  • Test predictions on ligand combinations not included in training sets

  • Generate and test novel antibody sequences with customized specificity profiles

  • Incorporate diverse experimental conditions to ensure robustness

• Advanced analysis:

  • Apply machine learning approaches to identify binding motifs

  • Use structural modeling to understand the molecular basis of specific interactions

  • Consider multiple rounds of selection with increasing stringency

  • Integrate high-throughput sequencing data with computational analysis

Recent research has demonstrated the successful application of biophysics-informed models to design antibodies with customized specificity profiles, either with high affinity for particular targets or with cross-specificity for multiple targets. These approaches have broad applicability beyond antibodies and offer powerful tools for designing proteins with desired physical properties .

How can CSNK2B antibodies be used to investigate the protein's role in cancer biology?

To study CSNK2B in cancer contexts:

• Experimental approaches:

  • Immunohistochemistry on tissue microarrays to correlate expression with clinical outcomes

  • Proximity ligation assays to detect cancer-specific protein interactions

  • ChIP-seq to identify cancer-specific IRF1-CSNK2B gene targets

  • Phospho-proteomics to identify altered CSNK2B-dependent phosphorylation in cancer cells

• Cancer-specific considerations:

  • IRF1 plays opposing roles in tumor progression, with CSNK2B potentially modulating these effects

  • Focus on pathways relevant to both cancer and CSNK2B function (e.g., Wnt signaling)

  • Consider cancer-specific post-translational modifications that may affect antibody detection

  • Investigate potential connections between CSNK2B's antiviral functions and cancer immunosurveillance

• Methodological challenges:

  • Tumor heterogeneity requires careful sampling and analysis

  • Potential alterations in CSNK2B expression or localization may necessitate protocol optimization

  • Distinguish between direct CSNK2B effects and indirect consequences of altered CK2 activity

  • Consider the broader context of casein kinase 2 signaling networks

• Therapeutic implications:

  • Correlate CSNK2B expression patterns with response to CK2 inhibitors

  • Investigate CSNK2B-dependent biomarkers of drug sensitivity

  • Consider dual targeting strategies for CSNK2B and its key partners

Research has identified that IRF1, a key CSNK2B-interacting partner, plays important but opposing roles in tumor progression, suggesting CSNK2B may similarly have context-dependent functions in cancer biology . Further clarifying the mechanisms by which CSNK2B modulates IRF1 binding to target DNA elements could provide the basis for developing both antiviral and anticancer therapies .

What techniques can researchers use to study the structural aspects of CSNK2B-antibody interactions?

For structural studies of CSNK2B-antibody interactions:

• Epitope mapping approaches:

  • Peptide arrays covering the full CSNK2B sequence

  • Hydrogen-deuterium exchange mass spectrometry

  • Mutational analysis of key residues

  • Competition assays with defined peptides or protein domains

• Advanced structural analysis:

  • X-ray crystallography of antibody-CSNK2B complexes

  • Cryo-electron microscopy for larger complexes (e.g., CSNK2B-IRF1-DNA)

  • NMR spectroscopy for mapping interaction interfaces

  • Molecular dynamics simulations to model conformational changes

• Functional validation:

  • Create antibodies targeting specific functional domains

  • Compare effects of different antibodies on CSNK2B activities

  • Assess impact on protein-protein interactions

  • Evaluate effects on enzyme activity of the CK2 complex

• Application-specific considerations:

  • For therapeutic applications, focus on antibodies that modulate specific CSNK2B functions

  • For diagnostic applications, prioritize antibodies recognizing native conformations

  • For research tools, develop panels of antibodies targeting distinct epitopes

  • Consider the impact of post-translational modifications on epitope accessibility

Understanding the structural basis of CSNK2B-antibody interactions can help develop more specific research tools and potentially therapeutic antibodies that modulate specific functions of CSNK2B in disease contexts.

What are the best practices for quantifying CSNK2B levels across different experimental conditions?

For accurate quantification of CSNK2B:

• Western blot quantification:

  • Use housekeeping controls appropriate to experimental context

  • Consider multiple loading controls to ensure validity

  • Apply linear range validation for both target and reference proteins

  • Use technical replicates and biological replicates (minimum n=3)

• Immunofluorescence quantification:

  • Establish consistent imaging parameters across samples

  • Use automated analysis where possible to reduce bias

  • Analyze sufficient cells per condition (typically >50)

  • Consider subcellular distribution as well as total signal

• Flow cytometry approaches:

  • Optimize fixation and permeabilization for intracellular staining

  • Include fluorescence-minus-one (FMO) controls

  • Use median fluorescence intensity rather than mean

  • Consider cell cycle effects on CSNK2B expression

• qRT-PCR considerations:

  • Validate reference genes under experimental conditions

  • Design primers spanning exon-exon junctions

  • Include no-RT controls to detect genomic DNA contamination

  • Analyze with appropriate statistical methods (e.g., ΔΔCt)

When studying CSNK2B's role in viral infection, researchers have found that even modest (50%) reductions in CSNK2B levels can have significant functional consequences, highlighting the importance of accurate quantification methods .

How should researchers interpret contradictory findings when studying CSNK2B functions in different experimental systems?

When facing contradictory results across experimental systems:

• Systematic analysis approach:

  • Create a comprehensive table of experimental variables (cell types, assays, conditions)

  • Identify consistent patterns within subsets of experiments

  • Consider whether differences are quantitative (magnitude) or qualitative (direction)

  • Evaluate the statistical power of each experimental system

• Biological explanations to consider:

  • CSNK2B has context-dependent functions (e.g., antiviral for some viruses, pro-viral for others)

  • Cell-type specific expression of interaction partners

  • Different isoforms or post-translational modifications across systems

  • Compensatory mechanisms that may mask effects in some systems

• Technical considerations:

  • Antibody specificity may vary across applications

  • Efficiency of genetic manipulations (knockdown vs. knockout)

  • Sensitivity and dynamic range of detection methods

  • Timing of measurements relative to perturbations

• Reconciliation strategies:

  • Design experiments that directly compare systems under identical conditions

  • Use complementary approaches (genetic and pharmacological)

  • Identify the specific factors that determine context-dependency

  • Consider developing mathematical models to explain divergent outcomes

Studies have demonstrated that CSNK2B can have seemingly contradictory roles depending on the virus being studied. For flaviviruses (DENV, ZIKV) and HAV, CSNK2B acts as an antiviral factor, while for other viruses like HCV and HIV, it may function as a pro-viral cofactor. Understanding these context-dependent functions requires careful experimental design and interpretation .